Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma".
作者信息
Crochet Gilles, Houot Roch
机构信息
Hematology department, CHU UCL Namur, Yvoir.
Hematology department, Centre Hospitalier Universitaire de Rennes, Rennes.
出版信息
Haematologica. 2025 Mar 1;110(3):808. doi: 10.3324/haematol.2024.286353.
Abstract
摘要
相似文献
1
Chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma".在接触双特异性抗体后，嵌合抗原受体T细胞疗法仍然有效。对《用于弥漫性大B细胞淋巴瘤治疗的细胞疗法和双特异性抗体的序贯治疗》的评论
Haematologica. 2025 Mar 1;110(3):808. doi: 10.3324/haematol.2024.286353.
2
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.
3
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.细胞治疗和双特异性抗体在弥漫性大 B 细胞淋巴瘤治疗中的应用测序。
Haematologica. 2024 Oct 1;109(10):3138-3145. doi: 10.3324/haematol.2024.285255.
4
Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.嵌合抗原受体T细胞疗法后复发或难治性大B细胞淋巴瘤：当前挑战与治疗选择
Br J Haematol. 2023 Apr;201(1):15-24. doi: 10.1111/bjh.18656. Epub 2023 Jan 29.
5
CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.嵌合抗原受体 T 细胞与双特异性抗体作为三线或更后线大 B 细胞淋巴瘤治疗的比较：一项荟萃分析。
Blood. 2024 Aug 8;144(6):629-638. doi: 10.1182/blood.2023023419.
6
Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.双特异性抗体在 CAR-T 时代复发/难治性弥漫性大 B 细胞淋巴瘤中的作用。
Front Immunol. 2022 Jul 19;13:909008. doi: 10.3389/fimmu.2022.909008. eCollection 2022.
7
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.两名弥漫性大 B 细胞淋巴瘤患者对嵌合抗原受体 T 细胞治疗耐药，对 odronextamab 有完全缓解。
Br J Haematol. 2022 Nov;199(3):366-370. doi: 10.1111/bjh.18383. Epub 2022 Jul 27.
8
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.老年弥漫大 B 细胞淋巴瘤患者管理中的挑战与机遇。
Oncologist. 2021 Feb;26(2):120-132. doi: 10.1002/onco.13610. Epub 2020 Dec 9.
9
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.在大B细胞淋巴瘤中，CAR T细胞疗法的疗效不会因先前的双特异性抗体治疗而受损。
Blood. 2024 Jul 18;144(3):334-338. doi: 10.1182/blood.2024024526.
10
Update on bi-specific monoclonal antibodies for blood cancers.血液癌症的双特异性单克隆抗体的最新进展。
Curr Opin Oncol. 2023 Sep 1;35(5):441-445. doi: 10.1097/CCO.0000000000000966. Epub 2023 Jul 5.
本文引用的文献
1
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.细胞治疗和双特异性抗体在弥漫性大 B 细胞淋巴瘤治疗中的应用测序。
Haematologica. 2024 Oct 1;109(10):3138-3145. doi: 10.3324/haematol.2024.285255.
2
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.在大B细胞淋巴瘤中，CAR T细胞疗法的疗效不会因先前的双特异性抗体治疗而受损。
Blood. 2024 Jul 18;144(3):334-338. doi: 10.1182/blood.2024024526.
3
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.连续双特异性分子暴露诱导的 T 细胞耗竭可通过无治疗间隔得到改善。
Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956.
Zotero 插件